Dr. Bearss will continue to lead SuperGen's discovery and pre-clinicaldevelopment strategies and execution as SuperGen continues to accelerate thediscovery and advancement into the clinic of novel drug candidates. Hisresponsibilities will include the oversight of target selection, productcreation and early stage development.
Advertisement
"As we move deeper into the frontiers of novel pharmaceutical space toaddress unmet medical needs, and expand our proprietary portfolio, Dave'sscientific vision and leadership, and his extensive research and developmentexperience, will continue to enable our Company to rapidly and efficientlyidentify, create and advance new drug candidates," said James S. Manuso,Ph.D., Chairman, President and CEO of SuperGen.
Advertisement
Dr. Bearss joined SuperGen as a result of the Company's acquisition ofMontigen Pharmaceuticals, Inc. in 2006. He cofounded and served as Montigen'sscientific leader. Dr. Bearss is at the core of SuperGen's scientificinnovation, and has enabled the discovery of the kinase inhibitors, MP-470 andSGI-1776. Emerging areas of his interest include the inhibition of protein-protein interactions, second-generation epigenetic inhibitors, and potentialtherapeutic applications of SuperGen's CLIMB(TM) discovery platform outside ofcancer. Dr. Bearss is a recognized expert in targeted small-molecule drugdevelopment and the use of genetic model systems for drug discovery andevaluation. He pioneered the development of new targeted therapeutics and hasbeen recognized for his work in validation and drug discovery projects withtargets including telomerase, nuclear hormone receptors and aurora kinases. In1999, as a fellow at the Cancer Therapy and Research Center (CTRC) in SanAntonio, Texas, Dr. Bearss collaborated with Dr. Daniel Von Hoff, a recognizedleader in drug development who has conducted more than 200 clinical trialswith new antineoplastic and biologic agents. Dr. Bearss subsequently joinedthe faculty of the University of Arizona as an Assistant Professor in theDepartment of Molecular and Cellular Biology and a member of the ArizonaCancer Center where he invented and developed several novel, targeted chemicalentities.
Dr. Bearss holds a B.S. degree from Brigham Young University and a Ph.D.in Cell and Molecular Biology from the University of Texas Health ScienceCenter at San Antonio. He has published more than thirty manuscripts and bookchapters and has won several awards for his scientific achievements. Dr.Bearss has served as a pharmaceutical industry consultant, with respect to thedevelopment of cancer therapeutics, for several biotechnology companies priorto founding Montigen Pharmaceuticals.
About SuperGen
Based in Dublin, Calif., SuperGen, Inc. is a pharmaceutical companydedicated to the discovery and development of novel cancer therapies. SuperGenis developing a number of therapeutic anticancer products focused on kinaseand cell signaling inhibitors and DNA methyltransferase inhibitors. For moreinformation about SuperGen, please visit http://www.supergen.com.
This press release contains "forward-looking" statements within themeaning of Section 21A of the Securities Act of 1933, as amended, and Section21E of the Securities Exchange Act of 1934, as amended, and is subject to thesafe harbor created thereby. The actual results could differ materially fromthose projected in the forward-looking statements as a result of a number ofrisks and uncertainties. These forward-looking statements include statementsregarding the ability of our products to enter clinical trials and thepotential validation of our discovery process to produce new compounds.SuperGen's products may not enter clinical trials and even if these productsdo enter clinical testing there is no assurance that these tests will besuccessful. Additionally, the early successes in preclinical work may not be avalidation of our discovery process and past success may not predict futuresuccess. Other factors that could cause actual results to differ materiallyfrom expectations include, but are not limited to, the risk factors detailedin the Company's filings with the Securities and Exchange Commission includingreports on its most recently filed Form 10-K and Form 10-Q. These forward-looking statements are made only as of the date hereof, and we disclaim anyobligation to update or revise the information contained in any such forward-looking statements, whether as a result of new information, future events orotherwise.Contacts: SuperGen Timothy L. Enns S.V.P., Corporate Communications & Business Development (925) 560-2810 [email protected] Dorland Global Public Relations Michael Beckerich (Media) Tel: (212) 677-7632 [email protected]
SOURCE SuperGen Inc.
